key: cord-1013700-d6o5pm97
authors: Della Guardia, Lucio; Codella, Roberto
title: Airways to heaven: caution needed when exercising during COVID-19
date: 2021-01-28
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2021.110522
sha: fac7825c88fac5feac68df1f124e50ccdaf9d312
doc_id: 1013700
cord_uid: d6o5pm97

nan

We read with particular interest the work of Heffernan et al.

"Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy" [1] which focuses on the protective role of exercise in SARS-Cov-2 infection, putatively by means of PPARα upregulation. Although suggestive, the article presents a couple of questionable arguments.

The modulatory activity of PPARα in the host-pathogen interaction is poorly characterized. For example, the study of Ehrilic et al. [2] , reporting

PPARα upregulation upon fenofibrate application on isolated alveolar cells, also shows that the infection itself is capable of upregulating alveolar PPARα gene (along with PPARγ and C/EBP), probably as a consequence of ER stress. Pharmacological stimulation of PPARα was shown to suppress INF-I, a molecule whose deficiency gives rise to a more severe form of infection [3] .

PPARs are also known to modulate oxidative stress, and specific ligands of each subtype may also display different results in regulating redox status. In addition, the efficacy of synthetic or dietary agonists in improving resistance to pathogen challenge is still controversial, making the role of PPARα in infectious diseases a debatable issue. 

Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy

Interferon deficiency can lead to severe COVID

Update on the Mechanisms of Pulmonary Inflammation and Oxidative Imbalance Induced by Exercise

The authors have no relevant financial or non-financial interests to disclose.

This article-letter did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.